Heinrich, M. C., Blay, J., Chi, P., Jones, R. L., Serrano, C., Somaiah, N., Gelderblom, H., Zalcberg, J. R., Reichmann, W., Sprott, K., Sherman, M. L., Bauer, S., George, S. (2025). INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with
            <i>KIT</i>
            exon 11 + 17/18 mutations.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.tps848